ViiV Healthcare announces FDA priority review designation for dolutegravir as a potential treatment for HIV infection
ViiV Healthcare today announced that the U.S. Food and Drug Administration (FDA) has granted a priority review designation to dolutegravir submitted for the treatment of HIV infection.
Source: GSK news - Category: Pharmaceuticals Source Type: news
More News: Food and Drug Administration (FDA) | Pharmaceuticals